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Highlights 
 There is substantial multimorbidity at mid-life but little is known about the strength of 
evidence on multimorbidity and health-related quality of life (HrQoL) at mid-life in the 
general population. Eight articles, from four databases, were identified for review.  
 Multimorbidity is consistently associated with poorer HrQoL at mid-life.  
 Two cross-sectional studies found that adults with multimorbidity at early mid-life reported 
poorer HrQoL than adults with multimorbidity at late mid-life, while another found the 
reverse.  
 Two distinct disease clusters were identified: mental health conditions, and cardiovascular 
disease (CVD). Those in the mental health cluster reported poorer HrQoL than those in the 
CVD cluster at mid-life. 
 Limitations of the selected studies include lack of longitudinal evidence, use of self-reported 
conditions and no assessment of disease severity or trajectory. Future research using a 
weighted disease severity index and multimorbidity trajectories based on longitudinal data is 
needed. 
 
Abstract  
There is substantial multimorbidity at mid-life but little is known about the strength of evidence on 
multimorbidity and health-related quality of life (HrQoL) at mid-life. This review addresses this gap, 
focusing on studies of the general population. PubMed, Web of Science, Embase and APA PsycNET 
databases were screened on 6 March 2017 for original research on multimorbidity and HrQoL in 
adults aged 40-65 years from the general population. Studies focused on index conditions, using 
single-item HrQoL measures, unlikely to represent the general population (e.g. primary care), and 
papers that were not in the English language were excluded. A narrative synthesis was presented 
due to heterogeneity in the measurement of multimorbidity. Of the 2557 articles, 83 underwent full 
text screening and 8 were included in the review. Included studies were of moderate to high quality 
and no exclusions were made on the basis of quality or bias.  Multimorbidity was associated with 
poorer HrQoL at mid-life. Two cross-sectional studies found that adults with multimorbidity at early 
mid-life reported poorer HrQoL than adults with multimorbidity at late mid-life, while another found 
the reverse. Two distinct disease clusters were identified: mental health conditions and 
cardiovascular disease (CVD). Those in the mental health cluster reported poorer HrQoL than those 
in the CVD cluster, women more so than men. Limitations of the selected studies include lack of 
longitudinal evidence, use of self-reported conditions and no assessment of disease severity. 
Multimorbidity is associated with poor HrQoL at mid-life at the population level, with some evidence 
of differences in association with age and disease cluster and sparse evidence on sex differences. 
Longitudinal research using a weighted disease severity index and multimorbidity trajectories is 
needed to strengthen the evidence base.   
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1. Introduction 
Multimorbidity, the co-occurrence of at least two health conditions in an individual [1-6], is an 
increasing health problem. It is brought about by population aging, unhealthy lifestyle habits, 
emerging chronic conditions, reduced mortality from improved medical care and technologies, and 
earlier detection and treatment of conditions [7]. Globally, multimorbidity prevalence is estimated 
to be between 3.5% and 100% [8].  The large variation is estimates observed is driven by differences 
definition and measurement of multimorbidity, population setting, participant age range, and 
country income levels [9]. Despite this, there is consensus that multimorbidity represents significant 
and growing burden to society [7]. Increased multimorbidity burden can lead to greater complexity 
in patient health management, reduced health related quality of life (HrQoL), and increased health 
care use and costs [10-12].  
While multimorbidity is common in older adults, studies have shown that those under 65 years old 
also experience a substantial multimorbidity burden [1, 13, 14, 15 ]. A recent systematic review  
highlighted a ‘S’ shape curve of multimorbidity prevalence with age [2],  where prevalence increased 
steeply at mid-life, and plateaued in those age 75 years and above. The onset of conditions at mid-
life may affect HrQoL. Previous systematic reviews on multimorbidity and HrQoL have focused on 
primary care populations[12, 16] or older adults (age 65+) [17] and have shown that multimorbidity 
is negatively associated with HrQoL in these populations. However little is known on the strength of 
evidence on multimorbidity and HrQoL at mid-life or at the general population level. Given the 
substantially higher prevalence and disease burden of multimorbidity in primary care compared to 
the general populations [18], there need for synthesis of evidence at a population level to assist in 
health service planning. 
It is unclear whether multimorbidity rates differ between males and females. The prevalence of 
multimorbidity is slightly higher in females compared to males, however findings are inconsistent [7, 
14, 19]. Some patterns of multimorbidity differ between males and females [19]. For example, 
depressive symptoms is more common in females while psychiatric and substance abuse is more 
common in young males [19]. These sex differences in prevalence and patterns of multimorbidity 
coupled with the onset of conditions at midlife may modify the association between multimorbidity 
and HrQoL. 
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This review aims to quantify the relationship between multimorbidity and HrQoL at mid-life, at the 
population level.  It will clarify whether the relationship is consistent between sexes, for different 
methods to measure multimorbidity, and between preference weighted and non-preference 
weighted HrQoL instruments. 
 
2. Methods  
2.1 Protocol and registration  
The corresponding review protocol is registered at PROSPERO (CRD42017056911).  
2.2 Study Selection 
This review focused on original quantitative epidemiological research that evaluated the association 
between multimorbidity and HrQoL in mid-age adults (aged 40 to 65 years) in the general 
population.  We also included cohort or cross-sectional studies on adults where separate estimates 
of multimorbidity and HrQoL were available for adults aged 40-65 years. For the purpose of this 
review, multimorbidity is defined as “multiple acute or chronic medical and/or psychiatric conditions 
which may or may not be related” [1-4]. Studies using validated measures of HrQoL which 
encapsulate multiple dimensions (e.g. physical function and psychological health) with 
multimorbidity definitions consistent with this review were considered eligible for inclusion. 
2.3 Search strategy  
Primary searches were conducted using PubMed, Web of Science, Embase and APA PsycNET 
databases, illustrated in Figure 1. Relevant studies available on 6 March 2017 were extracted from 
each database. Initial searches for each topic (multimorbidity, quality of life, adult, middle age, 
general population) were conducted separately, using a combination of keywords and subject 
headings (MeSH/Emtree/Thesaurus) terms (Supplementary data, Table A). Existing literature were 
used to identify common and popular keywords [1, 20]. Variants of terms including mis-spellings 
were also used as search terms (Supplementary Table A). As some studies use comorbidity to mean 
multimorbidity, keywords on “Co-morbidity” were also included in the search to capture all relevant 
literature. Parallel strategies were used to identify studies on quality of life, adults, at mid-life and 
from community settings. Search results were then combined using Boolean terms (Supplementary 
data, Supplement 1).  
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2.4 Selection Criteria 
One reviewer performed the 'Title-Abstract' screening process (JK), where literature was refined 
based on inclusion and exclusion criteria. Only peer reviewed articles published or were in-press 
were considered. No language or document type distinction was applied during the search. 
However, only original articles written completely in English were considered for full text screening, 
to ensure uniform level of comprehension of the articles. Full text were screened based on the 
inclusion and exclusion criteria to further refine the literature. 
Inclusion criteria: 
1) Original peer reviewed published or in-press research written in English 
2) Studies conducted in the general population that estimated the association between 
multimorbidity and HrQoL in mid-age adults (aged 40 to 65 years).  
3) Studies consistent with the definition of  HrQoL and multimorbidity described 
Exclusion criteria: 
1) Studies on single health conditions or focused on an index condition 
2) Studies unlikely to represent the general population (e.g. primary care, clinical setting, or 
specific patient or user populations) 
3) Studies which used single item self-rated health instrument to measure HrQoL 
2.5 Critical appraisal 
The critical appraisal of original papers was conducted independently by two reviewers (JK and MW) 
based on evaluation criteria adapted from Fortin et al. [12], used to assess for methodological 
quality (Supplementary data, Supplement 2). Each article was scored out of 30, based on criterions 
on originality, population studied, definition and measurement of multimorbidity and HrQoL, and 
limitations of the study. Risk of bias was assessed using an adapted version of the Newcastle-Ottawa 
Scale(NOS) [21] (Supplementary data, Supplement 3) suitable for observational studies, with good 
reliability and face validity [22]. Studies with scores of at least 15 out of 30 using the Fortin checklist, 
and 4 out of 9 stars using the NOS were eligible for data extraction and synthesis. There were no 
disagreements between the two reviewers eligibility of the included studies.  
2.6 Data extraction 
Data eligible for synthesis were extracted using a pre-defined questionnaire (see Supplementary 
Data, Supplementary Methods). The prevalence of multimorbidity defined as the presence of two or 
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more conditions (MM2+) or three or more conditions (MM3+) were reported. Multimorbidity 
prevalence is associated with aging [8]. Hence to ensure fair comparisons between studies when 
reporting prevalence of multimorbidity and its association with HrQoL, studies were grouped based 
on whether they were from adult populations spanning young to late adult life (Adult studies, age 
16+, n=5) [23-27] or studies focused at mid-life (Mid-life studies, age 40+, n=3) [28-30]. Prevalence 
specific to mid-life (age 40-65 years), and gender were reported where possible. However, as few 
studies report prevalence of multimorbidity specific to mid-life, overall prevalence in the study was 
presented to give an indication of the heterogeneity of multimorbidity across studies. Estimates on 
the association between multimorbidity and HrQoL (mean or mean difference), overall, and by life-
stage and gender were extracted where available. Due to substantial heterogeneity in the 
measurement of multimorbidity and in association with HrQoL, and ‘mid-life’ age groups across 
studies, meta-analysis was not performed, instead a narrative synthesis is presented. Additional 
details on data extracted for synthesis are available at Supplementary data, Supplement Methods. 
 
3. Results 
3.1 Study Selection: Overall description of screening/assessment process 
A total of 3698 articles were identified from the four databases, and 2557 were screened based on 
title and abstract (Figure 1). After full text screening and quality and risk of bias assessment, 8 
articles were included in the review, of which one article was identified from the reference list of an 
included article. All articles included in synthesis were moderate to high quality based on the Fortin 
and NOS assessments (Table 1). No articles were excluded on the basis of quality or risk of bias. 
During quality assessment, the main limitations with most studies were lack of results stratified by 
gender, insufficient or lack of information on non-responders or drop outs, and insufficient 
discussion of the limitations of the research. Common biases include lack of information on non-
responders, exposure information obtained from self-report, and the outcome of interest was 
present at the start of the study. 
3.2 Overall descriptions of studies  
Of the eight articles included in the review, three were from United States [26, 28]. Other studies 
were from Australia [27], New Zealand [30], France [29], Canada [25], Denmark [23] and Scotland 
[24] (Table 1). All studies were cross-sectional design (n=8). Data collection years ranged from 2001 
to 2013 while study sample sizes ranged from 1710 people to 47178. The majority of studies 
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included both genders (n=6, % female: 50.4-59.5), one studies was exclusively undertaken in female 
populations [28], while another reported it was a representative sample from the Scottish 
population but did not report gender balance [24]. Percentages of mid-age adults in these studies 
ranged from 31% to 100%. There was some heterogeneity in age ranges for ‘mid-life’ age groups 
across studies, however within age range of 40-65. All eight studies used a validated, multi-domain 
instruments to measure HrQoL, four used preference based HrQoL measures (AQoL-4D, SF-6D, EQ-
5D-3L). 
3.3 Multimorbidity measurement 
Multimorbidity was generally consistently defined as “the presence of two or more co-existing 
medical conditions” across four of the five studies which reported a definition for multimorbidity 
[25-27, 29] (Table 1). Lawson et al defined multimorbidity as the presence of two or more 
longstanding conditions from different systems of the body [24]. All studies used one data source 
(self-report surveys) to describe multimorbidity. Number of conditions used to define multimorbidity 
varied widely, from 6 to 118 conditions. Seven studies reported including only chronic conditions 
[24-30]. Two studies did not report a list of conditions used to define multimorbidity [26, 30]. The 
remaining six studies included both physical and mental health conditions [23-25, 27-29]. While one 
study used the Disease Burden Morbidity Assessment instrument to measure multimorbidity [25], 
most studies used a predefined list (n=7) to measure multimorbidity, using either self-reported 
conditions checklists or in combination with validated screening instruments. 
All studies used a count of conditions method to measure multimorbidity (Table 1). There was 
heterogeneity in how counts were grouped: 2+ vs < 2 conditions; 3+ vs < 3 conditions; 0, 1, 2, 3+ 
conditions; 0, 1,…., 9, 10+ conditions. Two studies also examined clusters of conditions [27, 29], with 
one calculating a disease association score which represent the number and strength of association 
between conditions within each cluster [29]. There were no studies that weighted for disease 
severity or described multimorbidity trajectories.  
Common chronic conditions included in nearly every multimorbidity list were cancer, stroke, 
diabetes, asthma, cardiovascular conditions (including hypertension), chronic obstructive pulmonary 
disease (COPD), mental health conditions (including depression and anxiety), arthritis conditions, 
osteoporosis, migraine/headaches, hearing impairment, allergies/hay fever and back pain (data not 
shown). One study included overweight or obesity (BMI ≥ 25 kg/m2) as a condition [25] which was 
highly prevalent (58.5%).  Of the four studies which reported prevalence of individual conditions, the 
prevalence of arthritis (n=2; %: 19 to 41), vision impairment (n=2; %: 8 to 40), osteoporosis (n=2; %: 
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9 to 31), asthma (n=2; %: 10 to 20) were heterogeneous across studies. There was less variation in 
the prevalence of hypertension (n=3; %: 24 to 28), and depression (n=3; %: 7 to 13). 
3.4 The prevalence of multimorbidity measured using count of conditions indices and 
the association between HrQoL and multimorbidity 
When multimorbidity was measured using count of conditions, mid-life studies generally reported 
higher prevalence of multimorbidity compared to adult studies (Table 2). Within each study, the 
prevalence of MM3+ was markedly lower compared to MM2+ in both study types, and across 
number of conditions groups [25, 27-29]. Differences in prevalence based on sex were observed, but 
direction was inconsistent in both population types [25, 27, 29]. Comparisons of multimorbidity 
prevalence in mid-life age range (40-65), in both population types, show that multimorbidity 
prevalence increases with age in mid-life [25, 27, 29].  
3.4.1 Association between HrQoL and multimorbidity at mid-life 
Seven of the eight studies examined the association between multimorbidity, measured using count 
of conditions and HrQoL [23-28, 30].  Multimorbidity was consistently associated with poorer HrQoL 
in the mid-life period, in adult and mid-life studies (Table 3). Findings were consistent amongst 
studies that reported preference weighted and non-preference weighted measures of HrQoL. Two 
cross-sectional studies found that adults with multimorbidity in early mid-life years reported poorer 
HrQoL than those at late mid-life years (Wang et al, mean AQoL-4D age 46-55 vs 56-65: MM 2+ 0.68 
vs 0.73; MM3+ 0.57 vs 0.66) [23, 27]. However, another cross-sectional study found that adults with 
multimorbidity in late mid-life report significantly poorer HrQoL than those in early mid-life [26]. 
None examined sex differences in the association between multimorbidity and HrQoL at mid-life. 
3.5 The prevalence of multimorbidity measured using multimorbidity cluster indices, 
and the association between HrQoL and multimorbidity 
Wang et al. examined clusters of conditions at a general population level and found a Cardiovascular 
disease (CVD)/Arthritis cluster (prevalence 9.1%) and a Major depressive disorder (MDD)/Anxiety 
cluster (prevalence 4.3%) [27]. On average, those in the MDD/Anxiety cluster were younger than 
those the CVD/Arthritis cluster (mean age 63.8 vs 41.7 years). The prevalence of each cluster was 
similar between males and females.  At mid-life, those with the MDD/Anxiety cluster of conditions 
reported markedly poorer HrQoL compared to those with the CVD/Arthritis cluster of conditions. At 
mid-life, those age 46-55 with CVD/Arthritis experienced poorer HrQoL, compared to those age 56-
65 (mean AQoL-4D age 46-55 vs 56-65: 0.68 vs 0.72), while for those with MDD/Anxiety, this 
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relationship was reversed with those at early mid-life experiencing poorer HrQoL (mean AQoL-4D 
age 46-55 vs 56-65: 0.49 vs 0.44). Sex differences were not examined in this research. 
Walker et al, using data from a mid-age population, found two clusters: cluster 1, predominately 
anxiety/depression, sleep troubles and body impairments (Anxiety/depression cluster), and cluster 2, 
predominantly CVD/metabolic diseases [29]. The researchers computed a multimorbidity score 
based on strength of association between conditions within cluster.  The higher the multimorbidity 
score, the greater the number and associations of morbidities [29]. In both males and females, 
multimorbidity scores increased with age for each cluster. Women reported higher scores for 
Anxiety/depression cluster than men, while men reported higher scores for the CVD/metabolic 
diseases cluster. At mid-life, those with Anxiety/depression clusters reported poorer physical and 
mental HrQoL, compared to those with CVD/metabolic disease clusters, females more so than males.  
In both males and females, differences were observed on impact of each cluster on physical and 
mental HrQoL between early and late mid-life. However, within each sex, the direction of association 
were inconsistent between different HrQoL measures used (Duke and SF-36).  
  
AC
CE
PT
ED
 M
AN
US
CR
IPT
4. Discussion 
This review highlights that recent data on multimorbidity and HrQoL at mid-life, using studies based 
on the general population is sparse, limited to cross-sectional research, and with substantial 
heterogeneity in the measurement and reporting of multimorbidity [4]. There were consistent 
findings across adult and mid-life studies that multimorbidity was associated with poorer HrQoL at 
mid-life. While there has been no review of the literature on multimorbidity and HrQoL focused at 
mid-life to date, this finding has been seen more broadly in primary care studies and in studies 
focused on adults age 65 and above [8, 12, 17].  
4.1 Age and sex differences  
Two cross-sectional studies suggest that adults with multimorbidity at early mid-life have poorer 
HrQoL compared to those at later mid-life [23, 27]. This may be due to initial adjustment periods 
associated with health transitions at mid-life, coupled adjustments to potential onset of new 
conditions or symptoms which together may result in poorer HrQoL early mid-life compared to late 
mid-life. Another cross-sectional study using age as a continuous variable found the reverse [26]. 
It is still unclear whether there are any sex differences in estimates of prevalence of multimorbidity 
at mid-life and its association with HrQoL. A previous primary care based review found that females 
report higher prevalence of multimorbidity compared to males, however evidence is mixed with 
some studies suggesting no significant difference [19]. Current evidence suggest that males generally 
report significantly higher HrQoL compared to females, a gap in HrQoL which widens at mid-life [31, 
32]. The number, type and onset of health changes at mid-life and its severity may differ between 
the sexes [33]. For females, timing of the onset of health symptoms and conditions due to 
menopause transitions during midlife is likely to affect HrQoL and result in higher prevalence of 
multimorbidity compared to age-matched males [34]. Alternatively males and females may adapt to 
health changes differently, which in turn may explain observed sex based difference in HrQoL during 
this period. Given the steep increase in multimorbidity prevalence at mid-life [2, 19], further 
research is needed using longitudinal cohort of mid-age males and females to clarify the role of sex 
and timing of multimorbidity onset in the association between multimorbidity and HrQoL. 
4.2 Measurement of multimorbidity 
When multimorbidity was measured using clusters of conditions, two distinct clusters emerge: one 
with mental health conditions, and the other with CVD; consistent with other research [35].  Across 
the two studies, those in clusters which include mental health conditions reported poorer HrQoL 
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than those in CVD clusters [27, 29]. This highlights the importance of mental health in the context of 
HrQoL and the need for multimorbidity studies to include mental health conditions as part of the 
pre-defined list of conditions [12].  There were inconsistencies in findings relating to age differences 
for these two studies. While such inconsistencies have been seen in other research [12], 
inconsistencies observed may be partly driven by differences in study populations (general adult 
populations vs Mid-life population), differences in analysis (analysis on overall sample vs analysis 
stratified by age and sex), and the heterogeneity in the measurement of multimorbidity.  
Almost all studies used count of conditions index to quantify multimorbidity when examining its 
association between HrQoL. While this method simple and can be used broadly across studies, it 
does not account for disease severity or duration of disease, both which can influence HrQoL [12]. 
No studies in this review used a weighted multimorbidity index or examined multimorbidity 
trajectories in association with HrQoL. As severity of conditions and  multimorbidity patterns of an 
individual may influence HrQoL, measuring multimorbidity with these methods may increase the 
validity and usefulness of findings than using a simple count of conditions [4]. Nevertheless, due to 
the heterogeneity of the measurement of multimorbidity, presenting results for count of conditions, 
in addition to another multimorbidity index is useful to assist with basic comparability across studies. 
Only two studies in this review examined clusters of conditions and its association with HrQoL [27, 
29]. Despite this, the demonstrated differential impact of clusters of conditions on health outcomes 
highlight the importance of multimorbidity studies which identify groups of conditions that co-occur. 
Further analysis examining age, life-stage and gender differences may assist in the targeted and 
early intervention of those at risk.  
4.3 Measurement of HrQoL 
All studies in this review used validated multi-domain instruments to measure HrQoL. Five studies 
assessed the impact of multimorbidity on physical and mental HrQoL domains separately while the 
remaining four used preference weighted measures of HrQoL which allowed assessment of 
multimorbidity on overall HrQoL [24]. Study findings were consistent between preference weighted 
and non-preference weighted HrQoL measures. Co-existing physical and mental health conditions in 
a multimorbid individual may impact multiple domains of quality of life. Hence, preference based 
measure of HrQoL may be more useful to quantify the impact of multimorbidity on overall HrQoL. 
Such measures summarises an individual’s HrQoL in a single score, by weighting multiple health 
domains based in its perceived importance as part of HrQoL [24]. Using preference based HrQoL 
measures are beneficial in health policy and planning as such data can help inform economic 
evaluations of health interventions targeted at those with multimorbidity [32].  
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4.4 Strengths and limitations 
To our best knowledge, this is the first review to assess available evidence on multimorbidity and 
HrQoL at mid-life. We summarised results from four bibliography databases and used a 
comprehensive list of keywords and topic headings, and targeted search strategies to ensure 
maximum coverage of articles. There may be relevant articles missed during the screening process 
due to language barriers (only articles in English were included), publication bias or available only as 
grey literature. We limited studies to those from general population to ensure estimates are 
generalizable at a general population level. Studies included were primarily from Western, high 
income countries, with predominantly Caucasian populations. Thus the findings of this review may 
only be generalizable to similar populations.  
The heterogeneity in the measurement and reporting of multimorbidity across these studies limits 
comparability across studies, thus a narrative synthesis of results was presented. There was variation 
in the number and types of conditions, grouping of conditions (individually e.g. depression vs in 
groups e.g. Depression/Anxiety)  used to define multimorbidity which may have influenced the 
prevalence reported and its associations with health outcomes [2]. While most studies used count of 
conditions to describe multimorbidity, there were differences in the multimorbidity thresholds used, 
and choice reference level for multimorbidity variable in association with HrQoL. All studies used 
self-reported conditions to define multimorbidity, which may result in under-reporting of conditions. 
Some studies did not report conditions used to describe multimorbidity [26, 30], while one study 
included overweight and obesity as a condition which likely have inflated its multimorbidity 
estimates [25]. All studies reported using only chronic conditions. However, including acute 
conditions and health symptoms specific to life-stage should be explored as it may influence 
HrQoL[12].  The definition of “Mid-life” varied across studies due to the variation age group interval 
lengths and cut points. To ensure some consistency across studies we included age groups generally 
captured the “mid-life” stage usually between ages 40 to 65years. Despite these limitations, the 
consistent findings on multimorbidity and HrQoL at mid-life provides some evidence of robustness of 
results.   
4.5 Implications public health, health policy and research 
This review highlights the need for longitudinal evidence on the association between multimorbidity 
and HrQoL at mid-life. The prevalence and combinations of conditions associated with 
multimorbidity differs based on life-stage [14]. However, there is a substantial multimorbidity 
burden at mid-life as seen in this review and in other research [15]. Given mid-life is a period of 
health transition and represents a critical period for health optimization [33], longitudinal evidence 
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on how the onset of new conditions and different multimorbidity trajectories influence HrQoL at 
mid-life is needed. To strengthen the evidence base, future research should also focus on 
investigating associated differences between early and late midlife using a cohort of men and 
women with repeated data over the midlife period (between ages 40-65 years). This may assist with 
patient care, target early interventions tailored to specific stages of mid-life, future health service 
planning and inform clinical guidelines on the management of people with multimorbidity at mid-
life. Our finding on the differential impact of CVD vs mental health clusters on HrQoL suggest that 
health care strategies for the management of people with multimorbidity may need to be tailored 
based on individuals’ combination of conditions as a whole (rather than based on single condition), 
considering both burden of treatment and disease, and patients’ health priorities and circumstances 
[36]. Adults with multimorbidity, with a mental health conditions may need a holistic, integrative 
approach to patient care incorporating both biomedical and psychosocial models of care [37].  
Multimorbidity indices that incorporate severity and duration of diseases are needed to better 
understand the combined effect of presence of disease, its severity and duration, and its influences 
on HrQoL. Using multiple indices to measure multimorbidity is recommended as different indices 
provide complementary information useful for different sectors of health. For example, from an 
epidemiological and health planning perspective, using count of condition to describe 
multimorbidity is useful to establish the prevalence of multimorbidity in a population which can 
inform service planning. However, for clinical practice and health policy, evidence on patterns and 
clusters of condition that tend to co-occur, and its impact HrQoL is more useful. Nevertheless, it is 
recommended that the prevalence of multimorbidity, defined using count of conditions, and its 
association with HrQoL is described in future research to facilitate comparisons across studies. 
Reporting of results overall, and with age and gender estimates, and including count of conditions in 
addition to other multimorbidity index will be useful to assist with basic comparisons across studies.  
Conclusion 
This review identified eight relevant studies and found consistently, multimorbidity was associated 
with poorer HrQoL at mid-life. There was some cross-sectional evidence of a difference in this 
association between early and late mid-life, and disease cluster, however more research is needed 
for conclusive findings. Given that the onset of morbidity at mid-life can affect HrQoL, research from 
longitudinal studies which measure multimorbidity using indices that incorporate severity of disease 
and disease trajectories is needed to strengthen the evidence base to assist with future health 
service delivery. 
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Figure 1 PRISMA flowchart of the selection procedure for articles used in the systematic review 
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Table and Figures 
Table 1 Characteristics of studies included in the systematic review 
Author 
(country) 
Quality 
score 
Study design Year data 
collected 
Population (age range, 
% female, % mid-age, 
Sample size) 
Mid-life 
age group a 
Multimorbidity HrQoL scale Study Limitations 
Adult studies (age 16+, n = 5) 
Wang et al. 
(2017) [27] 
Australia 
Fortin b: 29 
NOS c: 8 
 
Cross-sectional, 
private dwelling 
2007 Aged 16-85 years, 
mean age=44, 50.4% 
female, 31.7% mid age. 
N=8841 
46-55,  
56-65 
9 chronic conditions, 
obtained from self-report. 
MM measured using count 
of conditions (2+, 3+) and 
cluster of conditions 
Assessment of 
Quality of Life 
(AQoL-4D), 4 
domains, interview 
administered. 
Preference 
weighted-HrQoL 
Cross-sectional data. Did not 
incorporate diseases severity or 
duration in multimorbidity measure. 
Conditions self-reported, collected from 
face to face interview, but mental health 
conditions derived from diagnostic 
interview.  
Ramond-
Roquin et al. 
(2016) [25]  
Canada 
Fortin b : 28 
NOS c: 6 
 
Cross-sectional, 
part of cohort 
study 
2010 Community dwelling, 
aged 25-75 year, no 
major cognitive 
impairment, reside in 4 
local healthcare 
networks in Quebec. 
Mean age 51.3 (SD 
12.5). 59.5% women. 
N=1710 
46-64 Two chronic conditions lists 
(21 conditions; 6 condition 
list), self-report. MM 
measured using count of 
conditions (2+, 3+) 
Short Form 12 (SF-
12v2) PCS, self-
administered 
Cross-sectional data, under 
representative of young and deprived 
individuals. Did not incorporate diseases 
severity or duration in multimorbidity 
measure. Conditions list adapted from 
validated Disease Burden Morbidity 
Assessment but still self-reported. 
Included overweight and obesity (BMI ≥ 
25) as condition. Physical HrQoL 
estimated only. No HrQoL estimates for 
those without multimorbidity, only 
population norms. 
Juul et al. 
(2014) [23]  
Denmark 
Fortin b : 25 
NOS c: 6 
 
Cross-sectional 2013 20-90 years, 959 (52%) 
Females, 873 (47.7%) 
males. Overall mean 
age 58.3 (SD 18.7). 
N=1832 
50-49, 50-
59 
20 condition list, self-
reported. MM measured 
using count of conditions 
(0,1, 2+)  
European 
Organization for 
Research and 
Treatment of 
Cancer Quality of 
Life Questionnaire, 
EORTC QLQ-C30 
Global health 
status scale. Self-
administered 
Cross-sectional data. Did not 
incorporate diseases severity or 
duration in multimorbidity measure. 
Conditions self-reported. HrQoL 
instrument was developed for use in 
cancer patients, but adequate as a 
generic HrQoL measure. 
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Author 
(country) 
Quality 
score 
Study design Year data 
collected 
Population (age range, 
% female, % mid-age, 
Sample size) 
Mid-life 
age group a 
Multimorbidity HrQoL scale Study Limitations 
Lawson et al. 
(2013) [24]  
Scotland 
Fortin b: 27 
NOS c: 6 
 
Cross-sectional, 
household 
survey 
2003 Aged 18+, rep of gen 
pop across Scotland. 
37% mid-age N=7054 
45-64 40 chronic condition list 
reduced to 15 body systems. 
Conditions self-reported. 
MM defined as the presence 
of two or more longstanding 
conditions from different 
systems of the body.MM 
measured using 
dichotomous categories 
(MM2+, Not MM 2+) 
Short Form-6 
Dimension (SF-6D). 
Self-administered, 
Preference 
weighted HrQoL 
Cross-sectional data. Conditions self-
reported. Did not incorporate diseases 
severity or duration in multimorbidity 
measure. Data under representative of 
those in lowest SES. 
Sullivan et al. 
(2012) [26]  
United States 
Fortin b: 24 
NOS c: 6 
 
Cross-sectional, 
pooled 
household 
survey 
2001, 2003 Adults 18+, 52% 
female, 26% mid-age. 
N=47178 
45-58 118 chronic conditions 
(lasting >1 year) self-
reported, but conditions list 
not provided.  
Multimorbidity measured as 
count of conditions (0,1, 
2,….9,10+) 
EuroQoL-5 
dimension 3 level 
(EQ-5D 3L), self-
administered, 
Preference  
weighted HrQoL 
Pooled cross-sectional data. Conditions 
self-reported, but list of conditions not 
reported. Only chronic conditions were 
included (lasting 1 year or more). Used 
11-level number of conditions variable, 
rather than having 2+ or 3+ thresholds. 
Did not incorporate diseases severity or 
duration in multimorbidity measure. EQ-
5D scores using United States scoring 
algorithm exhibit strong ceiling effects 
hence may not be sensitive to 
discriminate within mild disease states. 
Mid-life population studies (age 18+, n = 3) 
Yeung and 
Breheny (2016) 
[30] New 
Zealand 
Fortin b: 21 
NOS c: 6 
 
Cross-sectional, 
part of 
longitudinal 
cohort study 
2012 Aged 50-87, mean age 
(SD) =66.1 (7.8), 56% 
female, 46% mid-age. 
N=2793 
50-64 14 chronic condition, self-
report but conditions list not 
provided. Multimorbidity 
measured as count of 
conditions (0, 1, 2, 3+) 
Short Form -12 (SF-
12) PCS and MCS, 
self-administered. 
Cross-sectional data. All conditions were 
self-reported. Number of conditions 
reported but list of conditions used 
were not reported. Did not incorporate 
disease severity or duration in 
measurement.  AC
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Author 
(country) 
Quality 
score 
Study design Year data 
collected 
Population (age range, 
% female, % mid-age, 
Sample size) 
Mid-life 
age group a 
Multimorbidity HrQoL scale Study Limitations 
Walker et al. 
(2016) [29]  
France 
Fortin b: 26 
NOS c: 5 
 
Cross-sectional 
design in cohort 
follow-up 
2007-2009 age 55+ at enrolment, 
mean age 63.2( SD 
4.9), 51.5% female,  
86% mid-age, N=5647 
55-59, 60-
64 
19 chronic condition, self-
reported. Multimorbidity 
measured as count of 
conditions (MM 2+) and 
disease association score.  
Medical Outcomes 
Study (SF-36 PCS 
and MCS), Duke 
Health Profile 
(Duke Physical and 
Mental Health). 
Self-administered 
Cross-sectional data. Examined 
associates stratified by age and gender, 
so no overall estimates of HrQoL in the 
sample. Self-reported conditions, but 
conditions used were selected based on 
relevance of overall health by a 
geriatrician.  Did not incorporate disease 
severity or duration in multimorbidity 
measure. Instead measured 
multimorbidity using a disease 
association score. 
Lang et al. 
(2015) [28]  
United States 
Fortin b: 23 
NOS c: 7 
 
Cross-sectional 2012 Female, aged 40-64 at 
data collection, English 
or Spanish speakers, 
N=3058 
40-64 6 chronic conditions, self-
reported using diagnostic 
scales. Multimorbidity 
measured using count of 
conditions (0, 1, 2, 3+) 
EuroQoL-5 
dimension 3 Level 
(EQ-5D 3L), self-
administered 
interviewed, 
Preference  
weighted HrQoL 
Cross-sectional data limited to women 
at mid-life stage and specific conditions. 
Too few conditions considered, and self-
reported conditions (using diagnostic 
tools) relevant to women at midlife only 
(Depression, Chronic pain, Urinary 
incontinence, Osteoporosis, Vasomotor 
symptoms, vulvar/vaginal atrophy). Did 
not incorporate diseases severity or 
duration in multimorbidity measure.  
EQ-5D scores using United States 
scoring algorithm exhibit strong ceiling 
effects hence may not be sensitive to 
discriminate within mild disease states. 
Note:   NOS, Newcastle-Ottawa Scale; HrQoL, Health related quality of life, MM, multimorbidity, MM2+, multimorbidity defined as two or more conditions; 
MM 3+, multimorbidity defined as three or more conditions, NA not available 
a Relevant Mid-life age-group (ages 40-65) reported in each study 
 
b Fortin M. Multimorbidity and quality of life in primary care: a systematic review. Health Qual Life Outcomes. 2004;2:51. 
c Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses: The Ottawa 
Hospital Research Institute;  [cited 2017 24/10/2017]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
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Table 2 Prevalence of multimorbidity in general population and mid-life studies by number of 
conditions 
 Adult studies (age 18+, n=5) Mid-Life studies (age 40+, n=3) 
 
< 8 8-14 15+ < 8 15+ 
          Studies RR 1 Wang 2 RR 1 Juul 3   Lawson 4 Sullivan 5 Lang 6 Yeung 7 Walker 8 
All age groups 
MM2+ 
     
 
   
Overall, % 13.8 26.0 63.8 36.0 18.0 44.0   63.0 
Male 16.0 23.8 65.6 36.4     60.0 
Female 14.4 27.9 62.5 35.7   31.0  67.3 
MM3+ 
     
 
 
 
 
Overall, % 3.8 10.1 48.9   29.0  50.0 40.5 
Male 4.8 8.7 50.8      36.6 
Female 3.2 11.4 47.6    13.0  44.1 
          Mid-Life age group 
MM2+ 
      
   Age groups a  46-55 56-65   45-64  40-64  55-59 60-64 
Overall, %  26.6 42.2   19.0    55.8 61.6 
Male     
     
44.5 56.7 
Female     
   
31.0 
 
61.6 66.7 
MM3+     
  
 
  
 
 
Age groups a  46-55 56-65     40-64  55-59 60-64 
Overall, % 
 
9.5 18.7       32.8 36.5 
Male  
  
 
      
22.5 31.8 
Female 
  
 
    
13.0 
 
38.0 41.4 
Note: RR, Ramond-Roquin et al.; MM, multimorbidity; MM2+, multimorbidity defined as two or 
more conditions; MM 3+, multimorbidity defined as three or more conditions, missing prevalence 
indicates prevalence was not reported 
1 Ramond-Roquin, A., Haggerty, J., Lambert, M., Almirall, J., Fortin, M., 2016. Different 
Multimorbidity Measures Result in Varying Estimated Levels of Physical Quality of Life in Individuals 
with Multimorbidity: A Cross-Sectional Study in the General Population. BioMed research 
international 2016, 7845438. 
2 Wang, L., Palmer, A.J., Cocker, F., Sanderson, K., 2017. Multimorbidity and health-related quality of 
life (HRQoL) in a nationally representative population sample: implications of count versus cluster 
method for defining multimorbidity on HrQoL. Health Qual Life Outcomes 15, 7. 
3 Juul, T., Petersen, M.A., Holzner, B., Laurberg, S., Christensen, P., Grønvold, M., 2014. Danish 
population-based reference data for the EORTC QLQ-C30: Associations with gender, age and 
morbidity. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, 
Care & Rehabilitation 23, 2183-2193. 
4 Lawson, K.D., Mercer, S.W., Wyke, S., Grieve, E., Guthrie, B., Watt, G.C., Fenwick, E.A., 2013. 
Double trouble: the impact of multimorbidity and deprivation on preference-weighted health 
related quality of life a cross sectional analysis of the Scottish Health Survey. International journal for 
equity in health 12, 67. 
5 Sullivan, P.W., Ghushchyan, V.H., Bayliss, E.A., 2012. The Impact of Co-Morbidity Burden on 
Preference-Based Health-Related Quality of Life in the United States. Pharmacoeconomics 30, 431-
442. 
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6 Lang, K., Alexander, I.M., Simon, J., Sussman, M., Lin, I., Menzin, J., Friedman, M., Dutwin, D., 
Bushmakin, A.G., Thrift-Perry, M., Altomare, C., Hsu, M.-A., 2015. The impact of multimorbidity on 
quality of life among midlife women: Findings from a U.S. nationally representative survey. J. 
Womens Health 24, 374-383. 
7 Yeung, P., Breheny, M., 2016. Using the capability approach to understand the determinants of 
subjective well-being among community-dwelling older people in New Zealand. Age Ageing 45, 292-
298. 
8 Walker, V., Perret-Guillaume, C., Kesse-Guyot, E., Agrinier, N., Hercberg, S., Galan, P., Assmann, 
K.E., Briançon, S., Rotonda, C., 2016. Effect of multimorbidity on health-related quality of life in 
adults aged 55 years or older: Results from the SU.VI.MAX 2 Cohort. PLoS One 11. 
a Relevant Mid-life age-group (ages 40-65) reported in each study. 
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Table 3 Synthesis of the association between multimorbidity (measured with count of conditions) 
and HrQoL at mid-life (age 40-65) 
Author 
MM exposure 
group 
Mid-life age 
range Overall results 
Early vs late mid-life 
HrQoL comparisons for 
those multimorbid 
Adult Studies (age 18+, n=5) 
Wang et al. 
(2017) [27] 
Australia 
MM2+ mean HrQoL 
scores compared to 
population norm a 
46-55, 56-65 ↓ AQoL compared 
to population 
norm a 
Late ↑ AQoL vs Early 
 MM3+ mean HrQoL 
scores compared to 
population norm a 
46-55, 56-65 ↓ AQoL compared 
to population 
norm a 
Late ↑ AQoL vs Early 
 MM2+ vs MM3+ 46-55, 56-65 MM 3+  ↓ AQoL vs 
MM2+ 
 
Ramond-
Roquin et al. 
(2016) [25] 
Canada 
MM2+ mean HrQoL 
scores compared to 
population norm b 
46-64 ↓ SF-12 PCS 
compared to 
population norm b 
NA 
 MM3+* MM mean 
scores compared to 
population norms b 
46-64 ↓ SF-12 PCS 
compared to 
population norm b 
NA 
 MM2+ vs MM3+ 46-64 MM3+ ↓ SF-12 
PCS vs MM2+ 
NA 
Lawson et al. 
(2013) [24] 
Scotland 
<2 (reference) vs 2+ 45-64 ↓ SF-6D NA 
Juul et al. 
(2014) [23] 
Denmark 
0, 1, 2+ 40-49, 50-59  ↓ EORTC  QLQ-
C30 Global quality 
of life with 
increasing number 
of conditions 
Late ↑ EORTC  QLQ-C30 
Global quality of life with 
vs Early 
Sullivan et al. 
(2012) [26] 
United States 
0,1,2,3,…,9, 10+ 45-58 ↓ EQ-5D with 
increasing number 
of conditions 
Late ↓ EQ-5D vs Early 
Mid-life studies (ages 40+, n=2) 
Yeung and 
Breheny 
(2016) [30] 
New Zealand 
0, 1, 2, 3+ 50-64 ↓ SF-12 PCS , ↓ 
MCS with 
increasing number 
of conditions 
NA 
Lang et al. 
(2015) [28] 
United States 
0, 1, 2, 3+ 40-64 ↓ EQ-5D with 
increasing number 
of conditions 
NA 
Note:   HrQoL, Health related quality of life, ↑ significantly higher mean scores with HrQoL, ↓ 
significantly lower mean scores with HrQoL, ↔ no significant difference in mean HrQoL. MM, 
multimorbidity, MM2+, multimorbidity defined as two or more conditions; MM 3+, multimorbidity 
defined as three or more conditions, NA not available 
a AQoL-4D Australian population norms based on Hawthorne and Richardson [38] 
b SF-12v2 PCS population norms  based  on Saris-Baglama et al. [39] 
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